A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Sep 2020 Results of pooled analysis from four studies (B-SHARE, ML21647, ML21165 and ML22452) presented at the 45th European Society for Medical Oncology Congress.
09 Dec 2017 Results (n=2056) presented at the 40th Annual San Antonio Breast Cancer Symposium.
11 Oct 2016 Results (n=2135) of a pooled analysis from ML21165, AVANTI and AVAREG studies assessing real-world effectiveness and safety in clinically important subgroups, presented at the 41st European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com